In November 2011, the U.S. FDA approved ruxolitinib (INCB018424) for the treatment of patients with intermediate or high-risk myelofibrosis. Ruxolitinib is an ATP-competitive inhibitor of JAK1 and JAK2 (IC50's of 3.3±1.2 nM and 2.8±1.2 nM
基本文件流程错误SQL调试用户
请求信息 : 2025-04-08 22:59:15 HTTP/1.1 GET : https://senovatech.com/anti_cancer949/289.html